Limits...
Molecular epidemical characteristics of Lamivudine resistance mutations of HBV in southern China.

Li SY, Qin L, Zhang L, Song XB, Zhou Y, Zhou J, Lu XJ, Cao J, Wang LL, Wang J, Ying BW - Med. Sci. Monit. (2011)

Bottom Line: Lamivudine (LMV), as the preferred oral drug for use in treatment of HBV, always results in development of resistance mutations after long-term treatment.For the mean age and sex ratio, no significant difference was found.Our results emphasize that a LMV resistance test before treatment is of great importance in rational and optimal CHB therapy.

View Article: PubMed Central - PubMed

Affiliation: Department of Laboratory Medicine, West China Hospital, Sichuan University, Sichuan Province, China.

ABSTRACT

Background: Lamivudine (LMV), as the preferred oral drug for use in treatment of HBV, always results in development of resistance mutations after long-term treatment. In this study we investigated chronic hepatitis B (CHB) patients in southern China to determine whether different HBV genotypes affect the incidence of LMV resistance mutations.

Material/methods: The study recruited 185 CHB patients living in southern China. Enzyme-linked immunosorbent assay was used to test for HBV serological markers, and HBV DNA was quantified by real-time PCR. Sequencing was performed to detect HBV genotypes and mutations.

Results: There were 49.19% (91/185) CHB patients with HBV resistant to LMV. Only 2 genotypes were found: B and C; 62.16% (115/185) of patients were infected with genotype B HBV and 37.84% (70/185) of patients were infected with genotype C HBV. The incidence rate of LMV resistance was not significantly different between genotype B and C (49.57% vs. 48.57%, P>0.05). For the mean age and sex ratio, no significant difference was found. The pattern of rtM204I alone was predominantly observed (36.26%, 33/91), followed by rtM204V+rtL180M (23.08%, 21/91). The overall incidence rate of rtM204I mutation in genotype B (45.61%, 26/57) was more frequent than that in genotype C (20.59%, 7/34) (45.61% vs. 20.59%, P<0.05), but the incidence rate of other mutation patterns was not significantly different between genotypes B and C.

Conclusions: Our results emphasize that a LMV resistance test before treatment is of great importance in rational and optimal CHB therapy.

Show MeSH

Related in: MedlinePlus

Distribution and frequency of age between two groups according gender.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3539467&req=5

f1-medscimonit-17-10-ph75: Distribution and frequency of age between two groups according gender.

Mentions: Figure 1 shows the distribution and frequency of age between the 2 groups. There was no significant difference between 2 groups with various age ranges in both females and males.


Molecular epidemical characteristics of Lamivudine resistance mutations of HBV in southern China.

Li SY, Qin L, Zhang L, Song XB, Zhou Y, Zhou J, Lu XJ, Cao J, Wang LL, Wang J, Ying BW - Med. Sci. Monit. (2011)

Distribution and frequency of age between two groups according gender.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3539467&req=5

f1-medscimonit-17-10-ph75: Distribution and frequency of age between two groups according gender.
Mentions: Figure 1 shows the distribution and frequency of age between the 2 groups. There was no significant difference between 2 groups with various age ranges in both females and males.

Bottom Line: Lamivudine (LMV), as the preferred oral drug for use in treatment of HBV, always results in development of resistance mutations after long-term treatment.For the mean age and sex ratio, no significant difference was found.Our results emphasize that a LMV resistance test before treatment is of great importance in rational and optimal CHB therapy.

View Article: PubMed Central - PubMed

Affiliation: Department of Laboratory Medicine, West China Hospital, Sichuan University, Sichuan Province, China.

ABSTRACT

Background: Lamivudine (LMV), as the preferred oral drug for use in treatment of HBV, always results in development of resistance mutations after long-term treatment. In this study we investigated chronic hepatitis B (CHB) patients in southern China to determine whether different HBV genotypes affect the incidence of LMV resistance mutations.

Material/methods: The study recruited 185 CHB patients living in southern China. Enzyme-linked immunosorbent assay was used to test for HBV serological markers, and HBV DNA was quantified by real-time PCR. Sequencing was performed to detect HBV genotypes and mutations.

Results: There were 49.19% (91/185) CHB patients with HBV resistant to LMV. Only 2 genotypes were found: B and C; 62.16% (115/185) of patients were infected with genotype B HBV and 37.84% (70/185) of patients were infected with genotype C HBV. The incidence rate of LMV resistance was not significantly different between genotype B and C (49.57% vs. 48.57%, P>0.05). For the mean age and sex ratio, no significant difference was found. The pattern of rtM204I alone was predominantly observed (36.26%, 33/91), followed by rtM204V+rtL180M (23.08%, 21/91). The overall incidence rate of rtM204I mutation in genotype B (45.61%, 26/57) was more frequent than that in genotype C (20.59%, 7/34) (45.61% vs. 20.59%, P<0.05), but the incidence rate of other mutation patterns was not significantly different between genotypes B and C.

Conclusions: Our results emphasize that a LMV resistance test before treatment is of great importance in rational and optimal CHB therapy.

Show MeSH
Related in: MedlinePlus